Schwab Charles Investment Management Inc. decreased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 155,146 shares of the biotechnology company’s stock after selling 10,732 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.21% of Arrowhead Pharmaceuticals worth $252,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in shares of Arrowhead Pharmaceuticals by 3.7% in the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after purchasing an additional 11,099 shares during the period. Geode Capital Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after purchasing an additional 21,654 shares during the period. UBS Asset Management Americas Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 414.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 53,500 shares during the period. Finally, Wells Fargo & Company MN boosted its position in Arrowhead Pharmaceuticals by 144.8% during the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after acquiring an additional 88,933 shares during the period. Institutional investors and hedge funds own 20.62% of the company’s stock.

A number of brokerages have commented on ARWR. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Cantor Fitzgerald restated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 25th. William Blair upgraded Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th. Chardan Capital restated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $2.00.

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) opened at $3.68 on Friday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $1.20 and a 1 year high of $5.01. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03.

WARNING: “Arrowhead Pharmaceuticals, Inc. (ARWR) Position Decreased by Schwab Charles Investment Management Inc.” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/11/arrowhead-pharmaceuticals-inc-arwr-position-decreased-by-schwab-charles-investment-management-inc.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.